文献速递白血病

老年急性髓系白血病患者一线低甲基化药物治疗失败后的结局:单中心经验

Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience.
PubMed 文献 · Am J Hematol · 2017-06-05

该单中心回顾性分析纳入56例以低甲基化药物(HMA)为一线治疗的老年急性髓系白血病(AML)患者,完全缓解10例(18%),总缓解率28%,中位缓解持续时间10个月。16例缓解者中13例(81%)复发,53例原发或继发失败患者失败后中位总生存(OS)仅2个月;12例接受后续治疗者无一例获得缓解,其中5例接受二次挽救治疗,2例(40%)获完全缓解;接受后续挽救治疗者中位OS优于未接受者(9.5个月 vs 2个月,P = .0009)。

要点

  • 56例以HMA为一线治疗的AML患者中,完全缓解10例(18%),总缓解率28%,中位缓解持续时间10个月。
  • 16例缓解者中13例(81%)复发,53例原发或继发失败患者失败后中位OS为2个月。
  • 12例接受首次挽救治疗者无一例获缓解;接受后续挽救治疗者中位OS为9.5个月,优于未接受者的2个月(P = .0009)。

核心结论

  • 原发或继发HMA治疗失败的AML患者结局很差,失败后中位OS仅2个月。
  • 本研究为未来针对此类患者亟需的新型治疗提供了重要的历史对照数据。

研究设计与样本

  • 单中心回顾性分析,纳入美国梅奥诊所(Mayo Clinic,罗切斯特)56例以HMA为一线治疗的AML患者。
  • 56例中15例(27%)接受阿扎胞苷(AZA),41例(73%)接受地西他滨。
  • 53例原发或继发失败患者纳入失败后分析;12例接受后续治疗,其中5例接受二次挽救治疗。

主要发现

  • 56例中完全缓解10例(18%),总缓解率28%,中位缓解持续时间10个月。
  • 16例缓解者中13例(81%)复发。
  • 53例失败患者失败后中位OS为2个月;其中12例(23%)接受后续治疗。
  • 12例接受首次挽救治疗者无一例获缓解;5例接受二次挽救治疗者中2例(40%)获完全缓解。
  • 接受后续挽救治疗者中位OS为9.5个月,未接受后续治疗者为2个月(P = .0009)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes of acute myeloid leukemia (AML) in elderly patients unfit for intensive chemotherapy is challenging. Hypomethylating agents (HMAs) can be effective in these patients but responses are usually short-lived. The majority of patients will either have stable disease or progress through therapy. We hereby describe the outcome of these patients at our institution after they fail HMAs. The data on 56 AML patients at Mayo Clinic, Rochester were reviewed. Patients were considered for our study if they received HMA as frontline therapy for their AML. Out of 56 patients, 15 (27%) patients received azacitidine (AZA) and 41 (73%) received decitabine. Complete remission was found in 10 (18%), with overall response of 28% and median response duration of 10 months. Thirteen (81%) out of 16 responders relapsed. Therefore 53 patients were included in the primary or secondary failure analysis with a median overall survival (OS) of 2 months after the date of failure. Out of 53 patients, 12 (23%) received subsequent treatments. None of the 12 patients who got first salvage therapy achieved remission. Five out of the 12 patients received second salvage therapy, 2 (40%) of which achieved CR. Median OS for patients who received subsequent salvage therapies was better than those who did not receive any subsequent therapy after failing HMA (9.5 vs. 2 months, P = .0009). Outcome for patients who have primary or secondary failure is very poor. Our study provides important historical data for future novel therapies, which are sorely needed for these patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Nanah R, McCullough K, Hogan W, et al. Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. Am J Hematol. 2017. PMID: 28474744. doi:10.1002/ajh.24780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。